Current medical research and opinion
-
Real-world characteristics of patients with sickle cell disease who initiated crizanlizumab therapy.
To provide real-word evidence of patients with SCD initiating crizanlizumab, their use of other SCD treatments, and crizanlizumab treatment patterns. ⋯ 66% of patients who receive crizanlizumab receive at least 4 doses within 6-months. The low median number of gap days suggests high adherence.